Scholar Rock Holding Corporation
SRRK
Pozycja w akcjach
#3503
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Cena akcji
$40.15
Kapitalizacja rynkowa
$4.89B
Zmiana (1 dzień)
0.63%
Zmiana (1 rok)
43.70%
Kraj
US
Handel Scholar Rock Holding Corporation (SRRK)
Kategoria
Healthcare
EPS dla Scholar Rock Holding Corporation (SRRK)
EPS na dzień June 2026 TTM: $-3.31
Według najnowszych raportów finansowych i ceny akcji firmy Scholar Rock Holding Corporation, obecny EPS (TTM) wynosi $-3.31. Na koniec roku 2023 firma miała EPS w wysokości $-1.99, spadek w porównaniu do do EPS z roku 2022, który wynosił $-2.21.
Historia EPS dla Scholar Rock Holding Corporation od 2016 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-3.31 | 34.01% |
| 2024 | $-2.47 | 24.12% |
| 2023 | $-1.99 | -9.95% |
| 2022 | $-2.21 | -38.44% |
| 2021 | $-3.59 | 29.60% |
| 2020 | $-2.77 | 53.89% |
| 2019 | $-1.80 | -42.86% |
| 2018 | $-3.15 | 125.00% |
| 2017 | $-1.40 | 53.85% |
| 2016 | $-0.91 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -623.26% |
US
|
|
| $-7.98 | 141.09% |
US
|
|
| $-5.29 | 59.82% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -938.07% |
NL
|
